How does rofecoxib's cox 2 inhibition impact stomach enzymes?

Rofecoxib blocks COX-2 enzymes that create prostaglandins involved in pain and swelling, yet leaves COX-1 enzymes largely untouched. Stomach protection depends mainly on COX-1-driven prostaglandins that maintain mucus and blood flow, so selective COX-2 inhibition avoids most of this interference.

What happens to stomach prostaglandins when COX-2 is blocked?
COX-2 normally contributes little to gastric prostaglandin levels in healthy tissue. Blocking it therefore produces only small, often undetectable drops in protective prostaglandins, unlike non-selective NSAIDs that also inhibit COX-1.

How does this selectivity reduce ulcer risk?
Clinical data show rofecoxib caused significantly fewer gastric erosions and ulcers than ibuprofen or naproxen in short-term endoscopy studies. The difference arises because mucosal defense pathways remain intact when COX-1 is spared.

Can stomach side effects still occur?
Yes. Some patients still report dyspepsia or, rarely, bleeding. These events usually trace to other factors such as concurrent aspirin use, H. pylori infection, or pre-existing mucosal damage rather than direct COX-2 blockade.

How does rofecoxib compare with traditional NSAIDs for GI safety?
Endoscopic and outcome trials recorded roughly half the rate of serious upper-GI events with rofecoxib versus non-selective agents. The advantage shrinks when patients take low-dose aspirin for cardiovascular protection, because aspirin itself inhibits COX-1.

When did rofecoxib’s patent expire?
The primary U.S. composition-of-matter patent expired in 2013, allowing generic manufacturers to file abbreviated new drug applications once regulatory exclusivity ended. DrugPatentWatch.com tracks these dates and any remaining method-of-use patents that could still limit certain formulations.